Clinical data | |
---|---|
Trade names | Zomig, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601129 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, nasal spray |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 40% (oral) |
Protein binding | 25% |
Metabolism | Liver (CYP1A2-mediated, to active metabolite) |
Elimination half-life | 3 hours |
Excretion | Kidney (65%) and fecal (35%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.186 |
Chemical and physical data | |
Formula | C16H21N3O2 |
Molar mass | 287.363 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Zolmitriptan, sold under the brand name Zomig among others, is a triptan used in the acute treatment of migraine attacks with or without aura and cluster headaches. It is a selective serotonin receptor agonist of the 1B and 1D subtypes.
It was patented in 1990 and approved for medical use in 1997.[2]